Vieworks Co., Ltd. (KOSDAQ:100120)
19,050
-240 (-1.24%)
Nov 21, 2025, 3:30 PM KST
Vieworks Revenue
Vieworks had revenue of 62.70B KRW in the quarter ending June 30, 2025, with 15.64% growth. This brings the company's revenue in the last twelve months to 225.23B, down -1.60% year-over-year. In the year 2024, Vieworks had annual revenue of 222.90B with 1.20% growth.
Revenue (ttm)
225.23B
Revenue Growth
-1.60%
P/S Ratio
0.76
Revenue / Employee
458.71M
Employees
491
Market Cap
170.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 222.90B | 2.65B | 1.20% |
| Dec 31, 2023 | 220.25B | -17.68B | -7.43% |
| Dec 31, 2022 | 237.93B | 44.79B | 23.19% |
| Dec 31, 2021 | 193.14B | 32.88B | 20.51% |
| Dec 31, 2020 | 160.26B | 24.25B | 17.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 5.50T |
| Celltrion | 3.90T |
| Yuhan | 2.17T |
| Hanmi Pharm. | 1.50T |
| SK Biopharmaceuticals | 675.41B |
| Sam Chun Dang Pharm. | 215.10B |
| ALTEOGEN | 158.06B |
| LigaChem Biosciences | 148.28B |